Desperate patients get early access to experimental brain drug
NCT ID NCT06594016
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers early access to fosigotifator, an oral drug, for people with Vanishing White Matter or Cree Leukoencephalopathy—two rare, serious brain diseases. A doctor must decide if the potential benefit outweighs the risks for each patient. The drug is not yet approved, so its effects are still being studied.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fosigotifator (oral drug)
What this could lead to
If this program provides benefit, it could point toward a treatment option for Vanishing White Matter and Cree Leukoencephalopathy.
What could go wrong
This is an expanded access program, not a formal trial, so data on safety and effectiveness is limited. The drug is still investigational and may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VANISHING WHITE MATTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.